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Abstract
Rationale Selective rapid eye movement sleep (REMS)
deprivation using the platform-on-water (“flower pot”)
method causes sleep rebound with increased REMS, de-
creased REMS latency, and activation of the melanin-
concentrating hormone (MCH) expressing neurons in the
hypothalamus. MCH is implicated in the pathomechanism
of depression regarding its influence on mood, feeding
behavior, and REMS.
Objectives We investigated the effects of the most selective
serotonin reuptake inhibitor escitalopram on sleep rebound
following REMS deprivation and, in parallel, on the activa-
tion of MCH-containing neurons.
Methods Escitalopram or vehicle (10 mg/kg, intraperitone-
ally) was administered to REMS-deprived (72 h) or home
cage male Wistar rats. During the 3-h-long “rebound sleep”,
electroencephalography was recorded, followed by an
MCH/Fos double immunohistochemistry.
Results During REMS rebound, the time spent in REMS and
the number of MCH/Fos double-labeled neurons in the lateral
hypothalamus increased markedly, and REMS latency showed
a significant decrease. All these effects of REMS deprivation
were significantly attenuated by escitalopram treatment.
Besides the REMS-suppressing effects, escitalopram caused
an increase in amount of and decrease in latency of slow wave
sleep during the rebound.
Conclusions These results show that despite the high
REMS pressure caused by REMS deprivation procedure,
escitalopram has the ability to suppress REMS rebound, as
well as to diminish the activation of MCH-containing neu-
rons, in parallel. Escitalopram caused a shift from REMS to
slow wave sleep during the rebound. Furthermore, these
data point to the potential connection between the seroto-
nergic system and MCH in sleep regulation, which can be
relevant in depression and in other mood disorders.
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Introduction
The crucial role of the serotonergic system in the regulation of
both sleep–wake states and mood is well documented
(Dugovic 2001; Monti 2011; Ursin 2002). Sleep disturbances
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belong to the core symptoms of depression, such as increase in
the amount of rapid eye movement sleep (REMS) and a
decrease in REMS latency (Steiger and Kimura 2010).
Selective serotonin reuptake inhibitors (SSRIs) are com-
monly used as effective antidepressants with a strong REMS
decreasing and REMS latency increasing effects (Steiger and
Kimura 2010; Wilson and Argyropoulos 2005). All these ef-
fects were also demonstrated in rodents (Monaca et al. 2003;
Vas et al. 2013). The main mechanisms existing in the back-
ground of REMS suppression of SSRIs imply the increase in
serotonin (5-HT) concentration via the inhibition of its reuptake
and the concomitant activation of postsynaptic 5-HT1A and 5-
HT1B receptors (El Mansari et al. 2005; Maudhuit et al. 1996).
The involvement of the lateral hypothalamus (LH) in sleep
regulation has been well established earlier (Gerashchenko and
Shiromani 2004). The melanin-concentrating hormone (MCH)
-containing cells in the LH and zona/subzona incerta (ZI/Sub
ZI) have been implicated first in the regulation of feeding and
metabolism (Bittencourt et al. 1992; Pissios 2009; Qu et al.
1996; Torterolo et al. 2011). Later, a strong connection between
MCH and REMS has been revealed (Kitka et al. 2011;
Torterolo et al. 2011). Local or intracerebroventricular admin-
istration of MCH to rodents caused a marked increase in
REMS; moreover, an elevated activation (increased Fos immu-
noreactivity) of MCH-expressing neurons has been reported
during REMS rebound after a long-term sleep deprivation
(Hanriot et al. 2007; Kitka et al. 2011; Modirrousta et al.
2005; Peyron et al. 2009; Torterolo et al. 2011; Verret et al.
2003). The increase in the time spent in REMS and the decrease
in the REMS latency during the rebound following sleep dep-
rivation are both changes similar to those described in depres-
sion. Furthermore, the antidepressant-like profile of MCH-R1
antagonists suggest the role of MCH in the regulation of mood
(Antal-Zimanyi and Khawaja 2009; Borowsky et al. 2002;
Chung et al. 2011; Lagos et al. 2011a; Millan et al. 2008).
Nevertheless, the effects of antidepressants on both the
activation of MCHergic neurons and REMS rebound after
sleep deprivation have not been studied yet. Here we demon-
strate that the most selective, relatively new, and clinically
effective (Ceglia et al. 2004; Leonard and Taylor 2010;
Montgomery et al. 2001; Wade et al. 2002) SSRI compound
escitalopram reduces Fos expression in MCH-immunoreactive
neurons in the LH.Moreover, escitalopram also diminishes the




All animal experiments and housing conditions were carried
out in accordance with the European Community Council
Directive of 24 November 1986 (86/609/EEC) and the
National Institutes of Health “Principles of Laboratory
Animal Care” (NIH Publications No. 85–23, revised
1985) as well as specific national laws (the Hungarian
Governmental Regulation on animal studies, 31 December
Psychopharmacology 1998 Act). Permission was obtained
from local ethical committees.
Male Wistar rats (n=36) were purchased from Animal
Facility (Semmelweis University, Budapest, Hungary). Rats,
weighing 346±6.14 g (mean ± SEM) at surgery, were kept
under controlled environmental conditions (temperature at
21±1 °C and a 12-h light–dark cycle starting at 10:00A.M.).
Food and water were available ad libitum during the whole
experiment.
Surgery
Rats were chronically equipped with electroencephalographic
(EEG) and electromyographic (EMG) electrodes, under halo-
thane (2%) anesthesia (Fluotec 3), as described earlier (Kantor
et al. 2004). Briefly, stainless steel screw electrodes were
implanted epidurally over the left frontal cortex (L=2.0 mm
and A=2.0 mm to bregma) and left parietal cortex (L=2.0 mm
and A=2.0 mm to lambda) for frontoparietal EEG recordings.
The ground electrode was placed over the cerebellum. EMG
electrodes (stainless steel spring electrodes embedded in sili-
con rubber; Plastics One Inc., Roanoke, VA, USA) were
placed into muscles of the neck. Rats were kept in single cages
in the recording chamber, and after a 7-day recovery period in
order to habituate the animals to the recording conditions, rats
were attached to the polygraph by a flexible recording cable
and an electric swivel, fixed above the cages, permitting free
movement of the animals (Filakovszky et al. 1999; Graf et al.
2004). To assess motor activity, electromagnetic transducers
were used in which potentials were generated by movements
of the recording cable as described earlier (Kantor et al. 2004).
Habituation period was 7 days long.
Groups
Animals were randomly divided into four groups as follows:
vehicle-treated home cage (HC-veh, n= 7) group,
escitalopram-treated home cage (HC-SSRI, n=7) group,
vehicle-treated REMS-deprived group (RD-veh, n=9), and
escitalopram-treated REMS-deprived (RD-SSRI, n=9) group.
REMS deprivation procedure
After the habituation period, rats were detached from the
electric cable and a 72-h-long REMS deprivation was
performed as described earlier (Kitka et al. 2009). Briefly,
the HC animals were placed into single cages, and each RD
animal was placed on a round platform (diameter=
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6.5 cm, surface was 0.5 cm above the water level)
situated in the middle of a round water tank (diameter=
41 cm). The REMS deprivation was started at lights on
and finished 72 h later. All animals were kept
undisturbed, and food and water were available ad
libitum during the REMS deprivation period. The “flower
pot” sleep deprivation paradigm was established to be
stressful for the animals; we addressed this question
extensively in our previous papers (Kitka et al. 2009,
2011). The conclusion of our studies was that REM
rebound and the activation of MCH neurons were strong-
ly associated with each other, but not with stress.
Furthermore, rats spent a considerable amount of time
swimming during our pilot experiments (unpublished da-
ta), suggesting that immobilization-induced stress is not a
major factor regarding this method. The schema of the
detailed experimental design is shown in Fig. 1.
Body weight and food intake measurement
Body weights of both HC and RD animals were measured
before and after the 72-h sleep deprivation period. For further
evaluations, the percent change in body weight was used.
Food intake of each animal was measured during both
REMS deprivation period and sleep rebound period. Rat
chow (150 g) was placed into the feeding tube of each
container for deprived animals and also 150 g for the HC
animals into their cages to allow ad libitum feeding for all
animals. The feeding tube was prepared in a way that the
loss was a strict measure of direct voluntary feeding.
Drug administration
After removing the animals from the platforms or home
cages and finishing body weight measurements, vehicle
(saline) or escitalopram oxalate (10 mg/kg, dissolved in
saline, provided by EGIS Plc., Hungary) were injected in a
volume of 1 ml/kgi.p. The injections were administered at
the beginning of sleep rebound to permit an undisturbed
sleep for both REMS-deprived and HC animals during the
3-h EEG recording (Sogaard et al. 2005; Vas et al. 2013).
EEG recording and evaluation
Immediately after the injections, all animals were re-
attached to recording cables in single cages. EEG, EMG,
and motility were recorded during a 3-h-long period (sleep
rebound). Rats were undisturbed throughout the recordings
and had free access to standard rodent chow and tap water.
The vigilance states were classified by SleepSign for
Animal sleep analysis software (Kissei Comtec America,
Inc., USA) for 4-s periods, as described earlier (Kantor et
al. 2004). In active wakefulness (AW), the EEG is charac-
terized by low-amplitude activity at beta (14–30 Hz) and
alpha (8–13 Hz) frequencies accompanied by high EMG
and intense motor activity. In passive wakefulness (PW),
also used as quiet wakefulness in the literature, the EEG is
characterized by low amplitude activity at beta (14–30 Hz)
and alpha (8–13 Hz) frequencies accompanied by high
EMG activity but minimal or no motor activity. In light
slow wave sleep (SWS1), high-voltage slow cortical waves
(0.5–4 Hz) were interrupted by spindles (6–15 Hz) accom-
panied by reduced EMG and no motor activity. In deep slow
wave sleep (SWS2), there were continuous high-amplitude
slow cortical waves (0.5–4 Hz) with reduced EMG and no
motor activity. In REMS, low-amplitude and high-
frequency EEG activity with regular theta waves (5–9 Hz)
were accompanied by silent EMG and motor activity with
occasional twitching.
The following parameters were calculated: duration of time
spent in each sleep stage per hour, the interval between sleep
onset and the occurrence of the first REMS and SWS2 period
(REMS latency and SWS2 latency, respectively), the number
and the average duration of REMS episodes per hour, and the
length of the first REMS episode. In order to exclude short
REMS attempts, a REMS episode was defined as a period of
REMS lasting for ≥16 s and not interrupted by ≥16 s of other
vigilance states (Gandolfo et al. 1996; Kitka et al. 2009, 2011;
Vyazovskiy et al. 2007).
MCH/Fos double immunohistochemistry
After the 3-h-long sleep rebound period, animals of both HC
and RD groups were anesthetized with sodium pentobarbital
(Nembutal, 35 mg/kg, i.p.; CEVA-Phylaxia) and transcardially
perfused using 4 % paraformaldehyde in 0.1 M phosphate
buffer, pH=7.4 (PB). The brains were removed, postfixed at
4 °C overnight, and cryoprotected in 20 % sucrose in PB
overnight. Then, 50-μm-thick coronal sections throughout
the hypothalamus were cut using a frigomobile (Frigomobile;
Fig. 1 Schematic illustration of the experimental design. Saline or SSRI
(escitalopram, 10 mg/kg, i.p.) treatments were applied following the
REMS deprivation (flower pot), or home cage stay, just before the
beginning of a 3-h sleep rebound (at lights on). Body weight changes
during the 72-h REMS deprivation and sleep parameters during the sleep
rebound were recorded. Immediately after the sleep rebound, all groups
were sacrificed and MCH/Fos double immunohistochemistry staining
was done. For more details, see “Materials and methods” section
Psychopharmacology (2013) 228:439–449 441
Reichert-Jung, Vienna, Austria). For immunostaining, solu-
tions were dissolved in PB and the primary antibodies were
applied for 2 days at 4 °C; all the other incubations were
performed at room temperature. The sections were washed
extensively for 3×10 min in PB between the incubation steps.
The sections were first permeabilized with 0.5 % Triton X-100
for 1 h. The endogenous peroxidase activity and the non-
specific antigen binding sites were blocked with the incubation
of the sections in 3 % hydrogen-peroxide solution and in 10 %
normal goat serum for 15 min and for 1 h, respectively. After
these steps, the sections were incubated in rabbit anti-Fos
(1:30,000, in PB; Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) primary antibody, and then in
biotinylated goat anti-rabbit IgG (1:1,000) and in avidin–bio-
tin–peroxidase complex (ABC, 1:500) for 1 h in both solutions
(both from Vector Laboratories, Burlingame, CA, USA). The
immunostaining was visualized by nickel-enhanced
diaminobenzidine (NiDAB) chromogen resulting in a dark
blue reaction product. Then, MHC immunostainings were
performed in the same way as the first one except using rabbit
anti-MCH as primary antibody (1:10,000 in 3 %
BSA/0.5 % Triton X-100 from Phoenix Europe GmbH,
Karlsruhe, Germany) and DAB, with chromogen resulting
a brown reaction product. Finally, the sections were col-
lected on gelatin-coated slides, dehydrated, and mounted
with DPX Mountant (Sigma-Aldrich, Budapest, Hungary)
mounting medium.
Morphometry analysis of MCH/Fos double immunolabeling
The amounts of MCH-immunoreactive (MCH-IR)/Fos-im-
munoreactive (Fos-IR) double-labeled and MCH-IR/non-
Fos-IR cells were determined in the lateral hypothalamus
(LH) bilaterally, in at least five 50-μm-thick coronal
sections between bregma −2.5 and −3.5 using a
Visopan microscope (No. 361977; Reichert, Austria)
(Paxinos and Watson 2007). Briefly, four randomly se-
lected non-overlapping areas were selected in each sec-
tion (0.64 mm2 altogether) under 40× objective, and the
quantification was made by the same observer in all
cases. Finally, the number of cells was calculated to cells
per square millimeter values.
For further analysis, activated portion of MCH-
containing neurons (MCH/Fos), namely the percent ratio
of MCH-IR/Fos-IR double-labeled cells per total number
of MCH-IR cells, was used.
Statistical analysis
Sleep parameters were evaluated by repeated measures
ANOVA with three main factors: rebound (as a result of
sleep deprivation; non-repeated; HC or RD), treatment (non-
repeated; vehicle or SSRI), and time (repeated; first, second,
and third hour of rebound) or by two-way ANOVAwith two
main factors: rebound (as a result of sleep deprivation; HC
or RD) and treatment (vehicle or SSRI). Post hoc analysis
(Tukey HSD test) was based on this latter two-way ANOVA
and indicated on figures. Immunohistochemical data was
also analyzed by two-way ANOVA with two main fac-
tors: rebound and treatment (see above). For post hoc
analysis, Tukey HSD test was used. For statistical anal-
ysis, STATISTICA 7.0 (StatSoft Inc., Tulsa, OK, USA)
software was used. Data in all figures are expressed as
mean ± SEM.
Results
Sleep parameters during the sleep rebound and the activated
portion of MCH-containing neurons in the LH were deter-
mined in the saline- (HC-veh and RD-veh) and escitalopram-
treated groups (HC-SSRI and RD-SSRI). Food intake and
body weight changes of all animals were measured during
the procedure.
Effects of REMS deprivation on sleep rebound
Time spent in different vigilance stages
The “time effect” was significant (p<0.005) in each
vigilance stage (AW, PW, SWS1, SWS2, and REMS) in
the investigated time period (from the first to the third
hour). In general, in the RD groups, the time spent in
AW, PW, and SWS2 decreased, while REMS increased
during sleep rebound, compared to HC groups (Fig. 2a,
b, d and Fig. 3a). The effects of rebound, as a result of
sleep deprivation, were significant in AW and REMS
(F1;17=5.42, p=0.0326 and F1;17=213.98, p<0.0001, re-
spectively), although in passive wake, only a strong
trend was observed (F1;17=4.45, p=0.0501). The time×
rebound interactions were significant both in SWS2 and
REMS (F2;34=10.43, p<0.001 and F2;34=21.45, p<
0.0001, respectively).
Specific REMS parameters
Comparing the HC and RD groups, the REMS latency
decreased, while the number and the average duration of
REMS episodes as well as the length of the first REMS
episode showed an increase during sleep rebound
(significant rebound effects—F1;17=419.70, p<0.0001;
F1;17=64.36, p=0.0001; F1;17=122.41, p=0.0001; and
F1;17=104.48, p<0.0001; REMS latency, number of
REMS episodes, average duration of REMS episodes,
and length of the first REMS episode, respectively;
Fig. 3b–d).
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SWS2 latency
We found significant rebound effect as a results of depriva-
tion, namely a decrease in the SWS2 latency in RD groups
compared to HC groups (F1;17=16.22, p=0.000875;
Fig. 3e).
Activated portion of MCH-containing neurons in the LH
The number of MCH-expressing neurons was not affected
by the REMS rebound (F1;17=0.0342, p=0.855).
The number of activated (Fos-positive) MCH-
containing neurons increased dramatically during sleep
rebound following REMS deprivation (RD vs. HC re-
bound effect—F1;17=517.95, p<0.0001; Figs. 4 and 5).
Effects of SSRI treatment in home cage
and REMS-deprived animals
Time spent in different vigilance stages
SSRI treatment decreased the time spent in REMS in the
home cage group (HC-SSRI) and even during sleep rebound
after deprivation (RD-SSRI; Fig 3a).
In case of REMS during the rebound, the following signif-
icant effects were found: a treatment effect (F1;17=29.04, p<
Fig. 2 The time spent in active wake (AW, a), passive wake (PW, b),
light slow wave sleep (SWS1, c), and deep slow wave sleep (SWS2, d)
in each hour of the 3-h-long sleep rebound. Saline or SSRI treatment
(escitalopram, 10 mg/kg, i.p.) was applied following the 72-h REMS
deprivation just before the beginning of sleep rebound. Note that
REMS deprivation has a decreasing effect on the time spent in AW,
PW, and SWS2 and escitalopram increases SWS2 in REMS deprived
rats. Data are represented as mean ± SEM. For significant ANOVA
results see Results section. *Significant post hoc effect of SSRI com-
pared to the appropriate saline control in the same hour (p<0.05).
Groups: vehicle-treated home cage (HC-veh), escitalopram-treated
home cage (HC-SSRI), vehicle-treated REMS-deprived group (RD-
veh), and escitalopram-treated REMS-deprived (RD-SSRI) groups
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Fig. 3 Changes in time spent in rapid eye movement sleep (REMS; a),
REMS latency (b), the number of REMS episodes (c), the average
duration of the REMS episodes (d), and SWS2 latency (e) in the 3-h-
long sleep rebound. Saline or SSRI treatment (escitalopram, 10 mg/kg,
i.p.) was applied following the 72-h REMS deprivation before the
beginning of sleep rebound. Data are presented as mean ± SEM. For
significant ANOVA results see Results section. *Significant post hoc
effect of SSRI compared to the appropriate saline control (p<0.05).
#Significant post hoc effect of REMS deprivation compared to the
appropriate home cage group in the same hour (p<0.05). Groups:
vehicle-treated home cage (HC-veh), escitalopram-treated home cage
(HC-SSRI), vehicle-treated REMS-deprived group (RD-veh), and
escitalopram-treated REMS-deprived (RD-SSRI) groups
444 Psychopharmacology (2013) 228:439–449
0.0001), time × treatment, rebound × treatment, and time ×
rebound × treatment interactions (in all cases, p<0.01).
Summarizing data of the 3-h-long sleep rebound, a
marked, almost three times increase in SWS2 was
observed in RD-SSRI group compared to RD-veh
group (rebound × treatment interaction—F1;17=4.20,
p=0.0562), and a 10-fold increase in the first hour
of SWS2 in RD-SSRI group compared to HC-SSRI
animals was also observable (Fig. 2d).
Specific REMS parameters
In HC animals (HC-SSRI group), SSRI treatment almost
completely abolished REMS.
As a result of escitalopram, we found an increase in REMS
latency as well as a decrease in both the number and the
average duration of REMS episodes during sleep rebound in
RD-SSRI group, compared to RD-veh animals (treatment
effect—F1;17=315.97, p<0.0001; F1;17=7.09, p=0.0164;
and F1;17=10.71, p=0.0045, respectively; Fig. 3b–d). A re-
bound × treatment interaction in REMS latency and a time ×
rebound × treatment interaction in the number of REMS
episodes were also significant (F1;17=176.63, p<0.0001;
and F2;34=5.58, p=0.0080, respectively).
SWS2 latency
In SWS2 latency, a significant rebound×treatment interac-
tion was found (F1;17=4.94, p=0.040167). Namely, SSRI
has an SWS2 latency-elevating effect when administered to
HC animals, but reduced SWS2 latency in REMS-deprived
animals during the sleep rebound (see Fig. 3e).
Activated portion of MCH-containing neurons in the LH
SSRI treatment significantly decreased the activated portion
of MCH-containing neurons during sleep rebound in RD-
SSRI group compared to RD-veh animals (Figs. 4 and 5).
Interestingly, a significant rebound × treatment interaction was
also found (F1;17=8.87, p=0.0084). In vehicle-treated ani-
mals, REMS rebound following REMS deprivation caused a
40-fold increase (RD-veh vs. HC-veh) in the activated (Fos
positive) portion of MCH-containing neurons. In contrast, in
SSRI-treated animals (RD-SSRI vs. HC-SSRI), there was
only a 10-fold increase in this parameter (see Fig. 4).
Correlations between REMS parameters and the activated
MCH-containing neurons
A general positive correlation could be seen between REMS
parameters and Fos% within the MCH-immunopositive
Fig. 4 Activated (Fos-positive) portion of MCH-containing neurons,
namely the percent ratio of MCH-IR/Fos-IR double-labeled cells per
total number of MCH-IR cells in the LH 3 h after the saline or SSRI
treatment (escitalopram, 10 mg/kg, i.p.) and the cessation of REMS
deprivation or beginning of sleep rebound. The drug treatment was
applied immediately after the REMS deprivation before the beginning
of sleep rebound. Data are presented as mean ± SEM. *Significant post
hoc effect of SSRI compared to the appropriate saline control (p<0.05).
#Significant post hoc effect of REM sleep deprivation compared to the
appropriate home cage group in the same hour (p<0.05). Groups: vehi-
cle-treated home cage (HC-veh), escitalopram-treated home cage (HC-
SSRI), vehicle-treated REMS-deprived group (RD-veh), and
escitalopram-treated REMS-deprived (RD-SSRI) groups
Fig. 5 Representation of individual REMS latency and activated Fos-
positive portion parameters in REMS-deprived vehicle (filled circles)
and REMS-deprived SSRI-treated (filled triangles) groups. REMS
latency during the 3-h REMS rebound and activated (Fos-positive)
portion of MCH-containing neurons, namely the percent ratio of
MCH-IR/Fos-IR double-labeled cells per total number of MCH-IR
(MCH-IR and MCH-IR/Fos-IR) cells in the LH 3 h after the saline or
SSRI treatment (escitalopram, 10 mg/kg, i.p.). Saline or SSRI treat-
ment was applied following the 72-h REMS deprivation just before the
beginning of sleep rebound. For correlation values see Results section
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cells when both rebound groups (RD-veh and RD-SSRI) are
plotted together, but the difference between the two groups
was not significant in any case, possibly due to the small
size of the sample. In the case of REM latency, where
escitalopram had a very strong effect, there were no
overlapping REMS latency data in the RD-veh and RD-
SSRI group; different slopes for the negative correlation
can be seen and calculated, but again, the correlation was
significant only if both groups were included in the same
analysis (r2=0.309, y=−9.298x+771.575, p=0.252, n=6;
r2=0.119, y=−27.715x+2,928.939, p=0.570, n=5; and
r2=0.426, y=−57.2832x+4,235.36, p=0.0296, n=11 for
RD-veh, RD-SSRI, and combined RD groups calculated
together, respectively; Fig. 6).
Changes in food intake and body weight during REMS
deprivation
Significant effects of REMS deprivation were found in both
parameters, namely an increase in food intake and a de-
crease in weight gain compared to home cage group (per-
cent body weight change; F1;18=13.70, p<0.01 and F1;16=
15.16, p<0.001, respectively). These effects were relatively
small in magnitude; the food intake during 72 h was 91.6±
4.4 g and 119.6±6.2 g in HC and REMS-deprived groups,
respectively. The percent body weight change during the
72 h of REMS deprivation was 108.4±1.2 % and 100.31±
1.7 % in HC and RD groups, respectively. Food intake and
percent body weight changes during the rebound period did
not differ significantly from zero (data not shown).
Discussion
Our study provides the first evidence that acute SSRI treat-
ment attenuates the activation of MCH-expressing neurons
in the lateral hypothalamus during the sleep rebound after
72-h-long selective REMS deprivation in rats. Furthermore,
our findings show that during the rebound sleep,
escitalopram is still able to reduce REMS despite the strong
REMS pressure. However, instead of increasing wake,
which is the case in home cage animals, it increases deep
slow wave sleep during the rebound sleep of the previously
REMS-deprived rats.
Sleep deprivation in different fashion was widely inves-
tigated as part of clinical therapy since it could reverse
depressive symptoms in approximately 50–60 % of de-
pressed patients (Gillin 1983; Hemmeter et al. 2010; Kuhs
and Tolle 1991; Landsness et al. 2011; Wirz-Justice and Van
den Hoofdakker 1999; Wu and Bunney 1990), showing
rapid effect on mood (Selvi et al. 2007). However, these
are acute effects; relapses usually come with the first epi-
sode of sleep, which is associated with a high REMS
pressure (Adrien 2002). Changes in vigilance stages during
rebound sleep of rodents after sleep deprivation are similar
to symptoms observable in depressed patients (Riemann et
al. 2001). The SSRI antidepressant escitalopram inhibits
REMS in depressed patients and, according to our results,
even during REMS rebound in rats. The usual REMS-
decreasing effect of escitalopram is observable in both HC
and RD animals in our study, although considering the
activation of the MCH-containing neurons, escitalopram
had a significant effect only in RD but not in HC animals.
The latter is probably due to a floor effect, as in basal
condition these neurons show a minimal, 1–2 % Fos posi-
tivity. It is in accordance with our earlier results where a
similarly small amount of MCH-containing neurons was
activated in control HC animals (Kitka et al. 2011). In
addition, the MCH-containing neurons occasionally fire
during transition from wake to SWS, and they reach their
maximal firing activity during REMS (Hassani et al. 2009),
which is probably lower than it could be during REMS
rebound (Peyron et al. 2009).
The acutely administered escitalopram, increasing extra-
cellular serotonin concentration, interferes with REMS and
MCH/Fos activity. Our previous paper (Kitka et al. 2011)
has demonstrated pronounced individual correlation be-
tween the number and the time spent in REMS versus Fos
activation of the MCH neurons during “rebound”. One
explanation could be the inhibition of the LDT/PPT cholin-
ergic neurons; the structure possesses a pivotal role in the
promotion of REMS. This inhibition is probably mediated
via 5HT1A receptors (Monaca et al. 2003). As serotonin
causes hyperpolarization of the hypothalamic MCH-
containing neurons as it has been shown in rat hypothalamic
slices (van den Pol et al. 2004), we cannot exclude that a
local mechanism causes hyperpolarization of MCH neurons,
too. In addition, MCH neurons have projections, among
others, toward the LDT/PPT nuclei and the dorsal raphe
nucleus (Torterolo et al. 2011), raising the possibility of a
further interaction among the two systems. Anyway, our
finding about MCH/Fos reducing the effect of escitalopram
raises several intriguing new questions regarding the clinical
effects of escitalopram and other SSRI antidepressants. One
of these could be that the effect of serotonin on MCH-
containing neurons (van den Pol et al. 2004) may be a
pivotal component in the antidepressant effect of SSRIs,
regarding that selective MCH1-R antagonist agents show
antidepressant-like effects (Borowsky et al. 2002; Gehlert et
al. 2009) and MCH administered into the dorsal raphe
evokes a depressive-like behavior (Lagos et al. 2011b;
Torterolo et al. 2011). In contrast, the role of REM reduction
may be questioned by the fact that there are other effective
antidepressants, such as bupropion, with its main effect on
the noradrenergic and dopaminergic system without affect-
ing the serotonergic system and not suppressing REMS
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either in human controls or depressed patients (Wilson and
Argyropoulos 2005). Besides, the antidepressant effect of
therapies modulating circadian rhythm (e.g., sleep depriva-
tion, phototherapy) may be based on changes in diurnal
variations of patients and are independent from REMS
attenuation (Bodizs et al. 2010; Selvi et al. 2007).
In a recent study, chronically administered fluoxetine (an-
other SSRI) also failed to cause any change in the activation of
MCH-containing neurons after the beginning of active phase
either in control rats or in animals exposed to chronic mild
stress (Nollet et al. 2011). However, the latter study was
performed after the beginning of the active phase, when
MCH neurons are mostly inactive, and they failed to examine
the activation of MCH immunoreactive neurons during
REMS or after a sleep deprivation experimental paradigm.
The high rate (452 %) activation of MCH neurons may be
specific to rebound sleep only and not observable in physio-
logical conditions (such as in HC rats). However, a higher
activation of MCH-containing neurons is conceivable also in
the sleep of depressed patients. Here, we demonstrate that
despite the high REMS pressure caused by REMS deprivation
procedure, escitalopram still has the ability to suppress REMS
during the rebound and, moreover, to inhibit the activation of
MCH-containing neurons, in parallel. We must note, of
course, that despite certain similarities between the alteration
of sleep parameters during sleep rebound in our experimental
design and the sleep of depressed people, the results of animal
studies are scarcely generalizable to the sleep conditions of
depressed patients.
Inconsistent data can be found in the literature regarding the
effects of SSRIs on wake and NREM sleep, namely that most
SSRIs decreased or did not change NREM sleep in depressed
patients (Murck et al. 2003; Winokur et al. 2001, 2003).
Besides, animal studies showed that elevated MCH level not
just antagonizes wake but has an increasing effect on SWS
even if in a minor extent only (Lagos et al. 2011a; Verret et al.
2003). Indeed, direct injection of MCH into the ventrolateral
preoptic region (VLPO) increased NREM sleep (Benedetto et
al. 2013). Our data show that during the sleep rebound after
long-term sleep deprivation, escitalopram is still able to reduce
Fig. 6 Illustrations of DAB/NiDAB MCH/Fos immunostaining of the
melanin-concentrating hormone (MCH)-expressing neurons in the lat-
eral hypothalamus (LH) on 50-μm-thick coronal sections of four
experimental groups: a vehicle-treated home cage (HC-veh), b vehi-
cle-treated REMS-deprived group (RD-veh), c escitalopram-treated
home cage (HC-SSRI), and d escitalopram-treated REMS-deprived
(RD-SSRI) group. The black reaction product visualizes Fos early
gene product in cell nuclei; brown depicts the MCH mostly in the
cytoplasm. Note the high rate of MCH/Fos double-labeled cells in both
RD groups (b, d), while in the HC groups, MCH/Fos double-labeled
cells among MCH-immunoreactive neurons are almost absent. Com-
paring RD groups (b, d), the decrease in Fos labeling of MCH-
containing cells in the SSRI-treated group (d) is apparent compared
to the vehicle-treated group (b). Between HC groups (a, c), no striking
difference in MCH/Fos double staining can be seen
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REMS, but instead of increasing wake, it increases deep slow
wave sleep. This is suggested also by the opposite effects of
escitalopram on SWS2 latency in home cage and deprived
animals. During the sleep rebound, caused by the mostly
selective REMS deprivation, the REMS pressure predominates
sleep, leading to a decrease in the amount of deep slow wave
sleep and total slow wave sleep (Kitka et al. 2009). Given the
fact that REMS deprivation by the “flower pot” method also
causes some slow wave sleep deprivation (Verret et al. 2003)
being much smaller in magnitude compared to REMS pres-
sure, the existence of a slow wave sleep pressure is also
feasible and suggested by rebound sleep data (Kitka et al.
2009). As the SSRI treatment interferes with the high REMS
pressure, we may conclude that the increased amount of deep
slow wave sleep can be the consequence of the slight SWS
deprivation. This is in line with the increased activation of
MCH neurons, even if decreased to some extent by the SSRI
treatment, as MCH has a potent role in the promotion of sleep,
and both SWS and REMS are facilitated by MCH, although
REMS is considered to be more sensitive to MCHmodulation.
This might explain the opposite effects of escitalopram in
home cage and deprived animals. Changes in slow wave sleep
may be relevant considering the beneficial cognitive effects of
SSRI antidepressants, but further studies are needed to eluci-
date mechanisms behind the common effects of antidepressant
and sleep deprivation (Bodizs 2009; Goder et al. 2011).
In conclusion, our main result shows that the SSRI anti-
depressant escitalopram reduces the activation of MCH-
containing neurons as well as the time spent in REMS
during rebound. Changes in the activation of MCH-
containing neurons by escitalopram may be relevant for
the clinical effects of SSRI antidepressants, although further
studies are needed.
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